Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 9.00
Ask: 9.50
Change: -0.65 (-6.74%)
Spread: 0.50 (5.556%)
Open: 9.50
High: 10.20
Low: 9.00
Prev. Close: 9.00
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

12 Oct 2022 15:12

RNS Number : 6903C
e-Therapeutics plc
12 October 2022
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

E Therapeutics Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights (See box 11)

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Dilution on placing of shares (See box 11)

X

3. Details of person subject to the notification obligationiv

Name

Richard Griffiths and controlled entities

City and country of registered office (if applicable)

Jersey, Channel Islands

4. Full name of shareholder(s) (if different from 3)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

10 October 2022

6. Date on which issuer notified (DD/MM/YYYY):

 

12 October 2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

29.28%

0.00%

29.28%

 

170,445,905

 

Position of previous notification (if

applicable)

26.39%

0.00%

26.39%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary

GB00B2823H99

170,445,905

29.28%

SUBTOTAL 8. A

170,445,905

29.28%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Serendipity Capital Limited

9.46%

9.46%

Ora Ventures Limited

10.99%

10.99%

Richard Griffiths and family

8.73%

8.73%

Cream Capital Limited

0.10%

0.10%

Total

29.28%

29.28%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

NA

The number and % of voting rights held

NA

The date until which the voting rights will be held

NA

11. Additional informationxvi

Notifier was diluted from 29.85% to 26.39% on admission of 67,500,000 placing shares on 6 October 2022 but subsequently made additional purchases to remain just above 29%.

 

 

 

 

Place of completion

Jersey, Channel Islands

Date of completion

12 October 2022

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEALEAFFAAFFA
Date   Source Headline
19th Feb 20139:45 amRNSDirector/PDMR Shareholding
15th Feb 20132:27 pmRNSDirector/PDMR Shareholding
14th Feb 20137:00 amRNSDirector/PDMR Shareholding
12th Feb 20134:08 pmRNSDirector/PDMR Shareholding
11th Feb 20133:38 pmRNSDirector/PDMR Shareholding
11th Feb 20137:00 amBUSe-Therapeutics to raise £40 million to advance lead cancer drug and exploit network pharmacology platform
8th Jan 20131:07 pmRNSHolding(s) in Company
18th Dec 20127:00 amBUSClinical Trial Update (ETS2101)
14th Nov 20123:30 pmRNSDirector/PDMR Shareholding
8th Nov 20126:01 pmRNSDirector/PDMR Shareholding
26th Oct 201210:25 amRNSDirector/PDMR Shareholding
23rd Oct 20125:23 pmRNSDirector/PDMR Shareholding
22nd Oct 20127:00 amBUSInterim Results for the six months ended 31 July 2012
2nd Oct 20128:57 amRNSDirector/PDMR Shareholding
25th Sep 20124:19 pmRNSDirector/PDMR Shareholding
12th Sep 20127:00 amBUSe-Therapeutics starts second phase I cancer trial of ETS2101
4th Sep 201211:00 amRNSNotice of Interim Results
6th Aug 20122:25 pmRNSAdditional Listing and Directors' Shareholdings
2nd Aug 20123:35 pmRNSAdditional Listing
31st Jul 20121:06 pmRNSResult of AGM
18th Jul 20125:14 pmRNSHolding(s) in Company
6th Jul 20122:08 pmBUSDirector/PDMR Shareholding
29th Jun 20121:03 pmRNSAnnual Financial Report
19th Jun 20127:00 amBUSe-Therapeutics' ETS2101 enters phase I clinical trial in brain cancer
22nd May 20127:03 amBUSe-Therapeutics' Preliminary Results for the Year Ended 31 January 2012
10th May 20127:00 amRNSNotice of Results
4th May 20126:00 pmRNSDirector/PDMR Shareholding
17th Apr 20123:55 pmRNSChange of Registered Office
29th Mar 20127:00 amBUSPhase I clinical trials of cancer drug ETS2101 approved by regulators
14th Mar 20125:59 pmRNSDirector/PDMR Shareholding
27th Feb 20127:00 amBUSPrime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford
8th Feb 20122:00 pmBUSe-Therapeutics to Present at The 14th Annual BIO CEO & Investor Conference
7th Feb 20128:41 amRNSHolding(s) in Company
6th Feb 20127:00 amBUSDirectorate Change
9th Jan 20122:00 pmBUSe-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference
30th Nov 20113:45 pmRNSDirector/PDMR Shareholding
27th Oct 201110:21 amRNSDirector/PDMR Shareholding
19th Oct 20117:00 amRNSInterim Results for the six months to 31 July 2011
26th Sep 20117:00 amRNSPatent for 'Power Behind the Throne'
21st Sep 20119:00 amRNSNotice of Interim Results
12th Sep 20111:06 pmRNSResult of AGM
17th Aug 20114:19 pmRNSDirector/PDMR Shareholding
15th Aug 20112:16 pmRNSDirector/PDMR Shareholding
9th Aug 201112:40 pmRNSDirector/PDMR Shareholding
28th Jul 201110:00 amRNSAnnual Financial Report
28th Jul 20117:30 amRNSDirector/PDMR Shareholding
25th Jul 20117:00 amRNSPreliminary Results and Business Update
29th Jun 20112:38 pmRNSNotice of Results
13th Jun 20117:00 amRNSDirectorate Change
6th Jun 20114:34 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.